Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 2/20 | 0.46 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.39 |
| ▸ | CALCR | P30988 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 4/20 | 0.38 |
| ▸ | FNTB | P49356 | 4/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | SCTR | P47872 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655801 | 0.93 | CTSL (0.44) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL31593289 | 0.90 | GLP1R (0.42) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL31157744 | 0.87 | CTSL (0.46) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL29721861 | 0.86 | APLNR (0.44) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL7447502 | 0.86 | GLP1R (0.53) | KEAP1PTH1RGLP1RSCTR | |
| SCHEMBL7447496 | 0.86 | GLP1R (0.53) | KEAP1PTH1RGLP1RSCTR | |
| SCHEMBL30571283 | 0.86 | KEAP1 (0.47) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL31467530 | 0.85 | NPY4R (0.41) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL31157717 | 0.85 | CTSL (0.49) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL31157718 | 0.84 | CTSL (0.48) | CTSLCTSSCTSKCTSHAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021415-B1 | CANNABINOID CONTAINING TARGETING LIPOSOMES | NEXTAGE THERAPEUTICS LTD (IL) | 2025-05-14 | — | — | EP | disclosed |
| US-20220305137-A1 | DRUG CONTAINING TARGETING LIPOSOMES | NEXTAR CHEMPHARMA SOLUTIONS LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| US-20220265555-A1 | CANNABINOID CONTAINING TARGETING LIPOSOMES | NEXTAGE THERAPEUTICS LTD. (IL) | 2022-08-25 | — | — | US | disclosed |
| EP-4021414-A1 | DRUG CONTAINING TARGETING LIPOSOMES | Nextar Chempharma Solutions Ltd. (IL) | 2022-07-06 | — | — | EP | disclosed |
| EP-4021415-A1 | CANNABINOID CONTAINING TARGETING LIPOSOMES | Nextage Therapeutics Ltd. (IL) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265555-A1 | CANNABINOID CONTAINING TARGETING LIPOSOMES | CNR2, CNR1, MAG | CTSL 708/4885CTSS 808/4885CTSK 1074/4885 |
| US-20220305137-A1 | DRUG CONTAINING TARGETING LIPOSOMES | LNPEP, FABP7, LAMP2 | CTSL 266/4885CTSS 764/4885CTSK 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.